Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious skeletal and cardiac muscle diseases. The company operates a proprietary drug discovery platform that utilizes high-throughput systems to identify small molecule modulators targeting key proteins in muscle tissue. Its primary business segments include muscular dystrophy and cardiovascular diseases. In the muscular dystrophy segment, the company is advancing sevasemten, an orally administered small molecule inhibitor designed to treat Duchenne and Becker muscular dystrophy. In the cardiovascular segment, Edgewise is developing EDG-7500, a selective cardiac sarcomere modulator for hypertrophic cardiomyopathy, and EDG-15400, a candidate for heart failure with preserved ejection fraction. The company also maintains a preclinical program, EDG-003, targeting cardiometabolic diseases. Edgewise retains global development and commercialization rights for all its programs and intends to build a focused commercial organization in the United States while evaluating strategic collaborations for markets outside the US. The company serves patients with rare neuromuscular and severe cardiac conditions, with a specific focus on unmet medical needs in the US, EU-5, and Japan.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage edgewisetx.com
Sector Healthcare IR page investors.edgewisetx.com/overview/default.aspx
Tags
muscular dystrophy, cardiovascular diseases, hypertrophic cardiomyopathy, heart failure, small molecule therapeutics, neuromuscular disorders, precision medicine, drug discovery, sevasemten, EDG-7500, EDG-15400, EDG-003
Press page —

Metrics

Valuation  
Market cap $ 4.978B
Market cap (USD) $ 4.978B
P/E 5.55
PEG —
P/BV 3.05
P/S —
P/OCF -24.66
P/FCF -34.55
Dividend yield —
Turnover / mcap —
Returns  
ROE -34.2%
ROI -36.2%
ROIC -30.9%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 72
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 552.603M 486.817M 340.035M 367.101M 285.233M 131.136M
Net profit -167.795M -133.813M -100.163M -67.64M -42.813M -17.123M
Free cash flow -144.072M -110.34M -97.693M -58.181M -34.175M -14.837M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 24.82 26.7 10.94 8.94 15.28 —
Price performance 12m -0.07 1.44 0.22 -0.41 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 4.41M 5.41M 4.74M 3.99M
Cash and deposits (USD) 23.7M 105M 15.6M 22M 86.1M 41.7M 61.1M
Right-of-use assets (USD) — — — 1.32M 2.25M 1.57M 1.39M
Cash flow detail
Operating cash flow (USD) — -14.6M -33.5M -52.6M -91.9M -109M -144M
Purchases of property, plant and equipment (USD) — -203,000 -668,000 -5.55M -5.75M -1.31M -256,000
Change in payables (cash effect) (USD) — 521,000 2.65M 47,000 -92,000 1.74M 272,000
Share-based compensation (USD) — 354,000 4.4M 10.9M 17.6M 24.7M 34.8M
Free cash flow (OCF - PPE - intangibles) (USD) — -14.8M -34.2M -58.2M -97.7M -110M -144M
Income detail
Research and development expense (USD) — 15M 32.2M 54M 90.9M 127M 151M
↳ 5y CAGR +58.8%
Total comprehensive income (USD) — -17.1M -43.3M -68.5M -98.7M -133M -168M
Comprehensive income to owners (USD) — -17.1M -43.3M -68.5M -98.7M -133M -168M
Reported May 13, 2021 Feb 24, 2022 Feb 24, 2022 Feb 23, 2023 Feb 22, 2024 Mar 3, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain –

– Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 –

– Dosed first patient in Phase 2 EQUINOX-HFpEF trial of EDG-15400 in heart failure with preserved ejection fraction (HFpEF) –

BOULDER, Colo., Nov. 4, 2026 — Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights.

“Our third quarter reflects continued execution across both cardiovascular programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.

close disclaimer

Cookie notice

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Accept AllReject All

Customize

close preference sidebar

Preference Center

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site.

We also use third-party cookies that help us analyze how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent.

You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.

Accept Recommended Cookies

Necessary

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Analytics

GTM option toggle on/off

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

close disclaimer

Cookie notice

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Accept AllReject All

Customize

close preference sidebar

Preference Center

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site.

We also use third-party cookies that help us analyze how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent.

You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.

Accept Recommended Cookies

Necessary

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Analytics

GTM option toggle on/off

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Prompts

Edgewise Therapeutics, Inc. (ticker EWTX), listed in United States.

ETFs Holding Edgewise Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
MMSC 0.90% 10,295 $ 449.686K Nov 16, 2026
FSEG 0.22% 303 $ 12.311K Jun 30, 2026
FESM 0.16% 226,451 $ 9.201M Jun 30, 2026
VFMO 0.14% 64,383 $ 2.689M Aug 31, 2026
DFAS 0.04% 267,923 $ 12.276M Nov 12, 2026
MSSM 0.02% 2,568 $ 107.265K Aug 31, 2026
DFAC 0.00% 3,311 $ 151.71K Nov 12, 2026
DCOR 0.00% 880 $ 40.322K Nov 12, 2026